Alzheimer Disease

Shire welcomes early date for Judicial Review of NICE decision on Alzheimer's treatments

Published in Lab Law Weekly, June 1st, 2007

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) welcomes the news that Monday 25 June 2007 has been set as the start date of the Judicial Review in the High Court to challenge the decision by the National Institute for Health and Clinical Excellence (NICE) to refuse NHS support of drugs for new patients with Alzheimer's disease of mild severity.

John Freeman, Managing Director of Shire's UK commercial operation says:

"Shire is pleased that, by arranging the hearing for the first possible date, James Goudie QC has acknowledged the importance and urgency of this matter to the general public and to the many thousands who will be diagnosed with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2007-06-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry